Patents by Inventor Tiphaine MOURET

Tiphaine MOURET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RET kinase inhibitors
    Patent number: 11970485
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: April 30, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • RET KINASE INHIBITORS
    Publication number: 20230265085
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 24, 2023
    Inventors: Gabrielle R. KOLAKOWSKI, Erin D. ANDERSON, Steven W. ANDREWS, Christopher Pierre Albert Jean BOLDRON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
  • RET kinase inhibitors
    Patent number: 11697647
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: July 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • RET KINASE INHIBITORS
    Publication number: 20220144816
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Gabrielle R. Kolakowski, Erin D. ANDERSON, Steven W. Andrews, Christopher Pierre Albert Jean BOLDON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO